TARS Insider Trading Activity and SEC Form 4 Filings
TARS insider trading summary
Over the past 12 months, insiders at Tarsus Pharmaceuticals, Inc. (TARS) reported 29 sales worth $10.7M by 7 insiders and no open-market purchases on SEC Form 4. Net insider selling was $10.7M.
Latest TARS insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 15, 2026 | William J Phd Link | Director | Sell | $5K (66 @ $80.01) |
| Sep 15, 2026 | William J Phd Link | Director | Sell | $60K (759 @ $79.00) |
| Sep 15, 2026 | William J Phd Link | Director | Sell | $915K (11,675 @ $78.33) |
| Sep 2, 2026 | Bobak R. Azamian | President/CEO and Board Chair | Sell | $801K (10,000 @ $80.06) |
| Sep 2, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sell | $431K (5,387 @ $80.00) |
| Sep 2, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sell | $127K (1,590 @ $80.00) |
| Sep 1, 2026 | Elizabeth Yeu Lin | Chief Medical Officer | Sell | $340K (4,601 @ $73.86) |
| Jun 17, 2026 | Bobak R. Azamian | President/CEO and Board Chair | Sell | $335K (5,418 @ $61.81) |
| Jun 17, 2026 | Bobak R. Azamian | President/CEO and Board Chair | Sell | $281K (4,582 @ $61.24) |
| Jun 16, 2026 | Jeffrey S Farrow | See Remarks | Sell | $877K (14,396 @ $60.95) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.